Resorba in treatment of prostate cancer patients with metastases in skeleton bones

The experience in administering Resorba to prostate cancer patients with skeleton bone metastases has been presented. It was shown that this agent controls pain, effectively protects bone tissue and contributes to bone tissue regeneration improving life quality of patients with metastatic hormone-resistant prostate cancer. The agent has also been shown to have limited side effects, well tolerated when used in combination with antitumor therapy and can be administered in outpatient settings.